Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug entities : Genmab a::S save search
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: -3.69%
H: 1.71%
C: -2.41%
PFE | News A | $26.26 1.0% 0.27% 110K
|
Health Technology
|
| O: 0.07%
H: 0.88%
C: -0.68%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: -1.1%
H: 0.46%
C: -0.06%
tivdak drug license review food cancer application
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-05-19 (Crawled : 16:00) - globenewswire.com
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: 0.61%
H: 1.26%
C: 1.24%
ABBV | News | $169.05 0.69% 66K
|
Health Technology
|
| O: 0.29%
H: 1.35%
C: 0.87%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: 0.54%
H: 2.0%
C: 1.81%
drug antibody approved food
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Published: 2022-12-21 (Crawled : 12:20) - biospace.com/
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: -5.08%
H: 5.66%
C: 3.35%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: -2.9%
H: 3.1%
C: 2.91%
cd20 duobody treatment drug japan application submission
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Published: 2022-11-21 (Crawled : 13:20) - globenewswire.com
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: 0.8%
H: 1.15%
C: -0.86%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: 0.46%
H: 0.43%
C: -0.71%
cd20 duobody treatment drug application license review food
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Published: 2022-06-30 (Crawled : 19:00) - globenewswire.com
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: -3.11%
H: 7.91%
C: 4.36%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: -0.77%
H: 3.85%
C: 3.69%
cd20 duobody treatment drug application license food
AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need
Published: 2022-06-13 (Crawled : 14:20) - biospace.com/
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: -4.61%
H: 5.03%
C: -1.29%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: -3.39%
H: 1.07%
C: -0.39%
drug
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Published: 2022-03-08 (Crawled : 13:00) - globenewswire.com
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: -0.14%
H: 5.36%
C: 5.36%
ABBV | News | $169.05 0.69% 66K
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: -0.3%
H: 3.38%
C: 0.32%
cd20 duobody drug granted drug designation food grant designation
Hematological Malignancies Drugs Market worth $ 42.78 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-08 (Crawled : 11:00) - prnewswire.com
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: -0.14%
H: 5.36%
C: 5.36%
TAK | News | $13.36 0.91% -0.08% 0
|
Health Technology
|
| O: -2.75%
H: 0.28%
C: -1.04%
JNJ | News | $148.88 -0.16% 940K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
GSK | News | $40.795 0.51% 150K
|
Health Technology
|
| O: 0.38%
H: 1.81%
C: 0.28%
BMY | $49.12 -0.04% 170K
|
Health Technology
|
| O: -1.55%
H: 0.71%
C: -0.28%
ABBV | News | $169.05 0.69% 66K
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
GILD | $67.55 0.9% 300K
|
Health Technology
|
| O: 1.4%
H: 0.7%
C: -1.15%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: -0.3%
H: 3.38%
C: 0.32%
AMGN | News | $273.97 0.76% 69K
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
ema drug report
Worldwide Drug Delivery Industry to 2027 - Growing Focus Towards Home Care and Self-Administration Presents Opportunities
Published: 2022-02-23 (Crawled : 18:00) - prnewswire.com
GNMSF | News | $289.67 5.3K
|
Health Technology
|
| O: 5.23%
H: 0.0%
C: -0.34%
GLAXF | News | $20.305 630
|
Health Technology
|
| O: -0.48%
H: 3.79%
C: 3.12%
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -1.1%
WST | $379.95 1.28% 5.6K
|
Health Technology
|
| O: 0.24%
H: 0.24%
C: -3.38%
NVS | News | $95.12 0.81% 4.36% 160K
|
Health Technology
|
| O: 1.82%
H: 0.07%
C: -1.0%
MDT | $80.57 1.37% 0.0% 150
|
Health Technology
|
| O: 0.5%
H: 0.25%
C: -1.16%
JNJ | News | $148.88 -0.16% 940K
|
Health Technology
|
| O: 0.23%
H: 0.7%
C: -0.18%
GSK | News | $40.795 0.51% 150K
|
Health Technology
|
| O: 1.9%
H: 0.07%
C: -0.87%
LLY | News | $731.33 0.69% 0.73% 12K
|
Health Technology
|
| O: 0.59%
H: 0.89%
C: -0.93%
BDX | $233.71 -0.07% 25K
|
Health Technology
|
| O: 0.22%
H: 1.9%
C: 1.48%
ABBV | News | $169.05 0.69% 66K
|
Health Technology
|
| O: 0.45%
H: 1.46%
C: 0.37%
MMM | $92.62 0.38% 0.14% 2K
|
Producer Manufacturing
|
| O: 0.0%
H: 0.4%
C: -1.61%
SNY | News | $47.15 1.84% 1.75% 11K
|
Health Technology
|
| O: 2.09%
H: 0.08%
C: -1.22%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: -1.67%
AZN | News | $70.48 0.5% 500K
|
Health Technology
|
| O: 1.43%
H: 0.0%
C: -1.85%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.29%
H: 0.87%
C: -2.6%
AMGN | News | $273.97 0.76% 69K
|
Health Technology
|
| O: 0.57%
H: 0.48%
C: -0.75%
drug liver growing drug delivery
Global Roundup: BioVersys Secures CARB-X Funds for Multidrug Resistant Research
Published: 2021-06-03 (Crawled : 14:15) - biospace.com/
DHR | $252.13 6.8% 610K
|
Health Technology
|
| O: -0.36%
H: 0.66%
C: -0.06%
GMAB | News | $28.97 9.3K
|
Health Technology
|
| O: -1.4%
H: 1.96%
C: 1.55%
drug research
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
ATGL | $3.66 27.97% 150K
|
KULR | $0.5446 22.0% 6.8M
|
Manufacturing
HIBB 4 | $85.785 18.34% 1M
|
Retail Trade
AZTR 4 | $0.222 13.85% 220K
|
n/a
INVO | $1.405 13.31% 270K
|
Health Technology
CANG | $1.5 11.94% 410K
|
Technology Services
CAN | News | $1.03 10.74% 2.4M
|
Electronic Technology
YS | $0.818 10.39% 5.6K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.